Macfarlanes has advised SV Health Investors on the closing of its latest fund, Dementia Discovery Fund 2 (DDF-2) closing above the target of $250m.

DDF-2 will continue to invest in early-stage therapeutics companies pursuing the development of high-impact therapeutics for age-related dementias, thereby seeking to address one of the largest global unmet medical needs. 

DDF-2 has attracted support from a strong group of institutional investors.

The Macfarlanes team was led by Private Funds Partner Harriet Miller with assistance from Senior Advisor Stephen Robinson, Senior Associate Miriam Cable and Associate Alex Nnadi. Tax advice was provided by Partner Sophie Donnithorne-Tait.

Christian Jung, Partner of SV Health Investors said: “We were delighted to work with Macfarlanes to help us achieve the closing of Dementia Discovery Fund 2. Their excellent support and advice was a key part of the successful achievement of this goal.”